Intraoperative Nerve Monitoring During Robotic-assisted Radical Prostatectomy

March 1, 2023 updated by: Alexander Nolsøe, Herlev and Gentofte Hospital

Can Intraoperative Nerve Monitoring Predict and Improve Functional Outcomes After Robotic-assisted Radical Prostatectomy

The purpose of this study is to evaluate whether the use of intraoperative nerve monitoring during robotic-assisted radical prostatectomy (RARP) can predict and improve post-surgery urinary continence and erectile function.

Study Overview

Detailed Description

Study design:

This is a single center, randomized, single blinded, prospective, clinical trial. The study population will comprise of 100 men that will undergo either a non-nerve sparring or unilateral-nerve sparring RARP. This means that the preoperative evaluation has suggested that it will not be possible to preserve the cavernous parasympathetic nerves lying in the fascia on either side of the prostate gland during surgery (called bilateral-nerve sparring). Despite the term, non-nerve sparring surgery, the surgeon will still attempt to preserve the somatic fibers of the pudendal nerve as best possible. However, due to the extent of cancer tissue the surgeon will generally need to operate closer to the pudendal nerve then when performing bilateral-nerve sparring surgery. So, the somatic fibers of the pudendal nerve are more likely to be severed. The same is the case on one side when performing unilateral surgery.

The treatment group will consist of 50 subjects that will undergo nerve monitoring during RARP. Results will be compared to a control cohort consisting of 50 patients that will undergo contemporary RARP.

Aside from the usage of nerve monitoring in the intervention-group, all procedures and care from admission to the hospital through discharge will be standard of care for subjects in both the control and Intervention-group.

Baseline evaluation and collection of data:

Patients will be screened for eligibility on the phone, and if eligible and they accept they will be scheduled to a visit at the hospital where the following data will be registered for all participants prior to surgery:

  • Age at time of surgery
  • Known co-morbidity
  • Body Mass Index (BMI)
  • Medicine status
  • Smoking
  • Partner status
  • Level of education
  • Employment Clinical status
  • Clinical stage (cT-staging)
  • Gleason score
  • Prostate specific antigen (PSA)

Prior to surgery participants will also have answered the questionnaires listed either prior to or during the first visit and have undergone an MRI and the bulbocavernosus-reflex test:

  • ICIQ (International Consultation on Incontinence Questionnaire) form about incontinence symptoms
  • Danish Prostate Symptom Score (DAN-PSS)
  • International Prostate Symptom Score (IPSS)
  • International Index of Erectile Function (IIEF) score
  • Erection Hardness Scale (EHS) score
  • Presence or absence of bulbocavernosus-reflex. The physician test for this by shortly squeezing the penis while observing if the urethra retracts or the anal sphincter contracts. The test is not painful and only takes a few seconds.
  • Magnetic Resonance Imaging (MRI) scan with measurements of the urethral length and width, and prostate volume along with other specific anatomical structures in relation to the urethra. Contrast agents will not be applied.

Intraoperative data:

  • Contraction of the sphincter musculature during stimulation via the nerve monitoring system before removal of the prostate gland
  • Contraction of the sphincter musculature during stimulation via the nerve monitoring system after removal of the prostate gland.
  • Blood loss
  • Non- or unilateral nerve sparring
  • Lymph node dissection
  • Total surgical time
  • Sphincter lesion
  • The surgeon's subjective prediction whether the patient will return to continence postoperatively

During the procedure, through discharge and before follow-up regime begins, the following data points will be collected:

  • Time to removal of catheter
  • Leakage of the anastomosis
  • Stricture.
  • Other adverse effects
  • Pathologic cancer stage (pT-stage)
  • Pathologic Gleason score
  • Status of surgical margins

Follow-up evaluation.

Subjects will be evaluated 14 days after catheter removal and at standard clinical controls at 3, 6 and 12 months. The following questionnaires are answered at every visit:

  • International consultation on Incontinence Questionnaire (ICIQ) for incontinence,
  • Danish Prostate Symptom Score (DAN-PSS)
  • International Prostate Symptom Score (IPSS)
  • International Index of Erectile Function (IIEF) and Erection Hardness Scale (EHS).

During the last 3 visits subjects also answers a fluid intake/output questionnaire and hand in the results of a 24-hour pad test. In addition to the questionnaires the patients will also undergo an MRI and a bulbocavernosus reflex test 12 months postoperative.

Study Type

Interventional

Enrollment (Actual)

100

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Central Region
      • Herlev, Central Region, Denmark, 2730
        • Herlev and Gentofte Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • Patients that are planned to undergo either non-nerve or unilateral nerve sparring surgery.
  • Patients that deemed able to understand the protocol and to return for all the required post-treatment follow-up visits.

Exclusion Criteria:

  • Incontinence prior to surgery
  • Diabetes
  • Known neurological disease that can affect urinary/erectile function
  • Condition with Pacemaker
  • Previous pelvic trauma
  • Previous pelvic surgery including transurethral resection of the prostate
  • Previous pelvic radiation therapy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intraoperative nerve monitoring
Patients that undergo robotic-assisted radical prostatectomy with the use intraoperative nerve monitoring, via electromyography, to identify the exact location of the somatic fibers in the pelvic nerves that seem crucial for urinary continence control and erectile function
Intraoperative nerve monitoring, via electromyography, enables real-time identification of the location of the somatic fibers in the pelvic nerves that seem crucial for urinary continence control and erectile function.
Active Comparator: Control Cohort
Patients that undergo standard of care robotic-assisted radical prostatectomy.
With out the usage of intraoperative nerve monitoring

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Return of continence following robotic-assisted radical prostatectomy
Time Frame: 12 months

Difference in total International consultation on incontinence questionnaire (ICIQ)-score between the 2 groups after a follow-up of 1 year.

ICIQ is a self-reported survey and screening tool for incontinence. It consists of 3 questions regarding symptoms in the past 4 week, with an overall 0-21 score, where greater values indicate increased severity. Question 1 scores from 0-5, question 2 scores either 0,2,4 or 6 and question 3 scores from 0-10. Only the total score is evaluated. Furthermore there is 1 self-diagnostic question.

12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Return of erectile function following robotic-assisted radical prostatectomy
Time Frame: 12 months
Difference in erection rates and sexual activity between the 2 groups after 12 months. Sexual activity defined as yes to the question "Within the last 3 months, have you been sexually active and attempted intercourse?" Erection is defined as a score of at least 17 on the IIEF-5 form and or a score of a least 3 on the EHS form with the use of either no assistance phosphodiesterase 5 inhibitors
12 months
Nerve function prior to removal of the prostate correlated to patient's preoperative urinary function
Time Frame: 1 day
Correlation between nerve signal prior to removal of the prostate and preoperative urinary function
1 day
Nerve function prior to removal of the prostate correlated to patient's preoperative erectile function
Time Frame: 1 day
Correlation between nerve signal prior to removal of the prostate and preoperative erectile function
1 day
Nerve function after removal of the prostate correlated to patient's postoperative urinary function
Time Frame: 12 months
Correlation between nerve signal after removal of the prostate and postoperative urinary function
12 months
Nerve function after removal of the prostate correlated to patient's postoperative erectile function
Time Frame: 12 months
Correlation between nerve signal after removal of the prostate and postoperative erectile function
12 months
Difference in the degree of incontinence between the two groups for incontinent patients.
Time Frame: 12 months
Measured in gram on the 24-hour pad test
12 months
Difference in Time to continence between the two groups
Time Frame: 12 months
Difference in Time to continence between the two groups
12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 21, 2018

Primary Completion (Actual)

June 3, 2022

Study Completion (Actual)

June 10, 2022

Study Registration Dates

First Submitted

October 25, 2018

First Submitted That Met QC Criteria

October 25, 2018

First Posted (Actual)

October 26, 2018

Study Record Updates

Last Update Posted (Actual)

March 2, 2023

Last Update Submitted That Met QC Criteria

March 1, 2023

Last Verified

March 1, 2023

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Urinary Incontinence

Clinical Trials on Intraoperative nerve monitoring,

3
Subscribe